Български
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
hypoglycemia/епилептични припадъци
Линкът е запазен в клипборда
Страница 1 от 52 резултата
Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
FIELD OF THE INVENTION
The invention provides cyclohexylamine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists, pharmacological compositions comprising the derivatives, and methods of treating diseases and disorders responsive to antagonism of NMDA receptors using the derivatives.
BACKGROUND
Substituted 2,3-benzodiazepin-4-ones and the use thereof
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
This application claims benefit of U.S. provisional application Ser. No. 60/013,813 filed Mar. 21, 1996.
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is in the field of medicinal chemistry. In particular, the invention relates to novel substituted 2,3-benzodiazepin-4-ones.
4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs, as well as novel intermediates of the 4-substituted analogs. The analogs are selectively active as antagonists of
4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs, as well as novel intermediates of the 4-substituted analogs. The analogs are selectively active as antagonists of
2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as
2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as
4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also
Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
FIELD OF INVENTION
The invention relates to piperidine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists useful in the treatment of diseases and disorders responsive to antagonism of NMDA receptors.
BACKGROUND OF THE INVENTION
Many of the physiological and pathophysiological effects of the
Substituted quinoxaline-2-ones as glutamate receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the substituted quinoxaline 2-ones type. The compounds are active as excitatory amino acid receptor antagonists acting at glutamate receptors, including either or both
Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
The present invention concerns novel sulfonamide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by sulfonamide derivatives. The
Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
This invention is for novel glutamate receptor antagonists which are new compounds of the 5,6,7,8-substituted quinoxaline 2,3-diones type. The fused ring system is substituted at the a or b position by amino acid derivatives. The compounds are active as excitatory amino
Therapeutic method for management of diabetes mellitus
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
The invention relates to a method of using tetracycline compounds in the treatment of diabetes. Specifically, the invention relates to a therapeutic method of using tetracyclines in managing patients suffering from pathological conditions associated with diabetes
Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
FIELD OF THE INVENTION
The present invention is in the field of medicinal chemistry and relates to compounds that have a high affinity for the glycine binding site, lack PCP side effects, and cross the blood brain barrier at high levels. In particular, the present invention relates to pyridine and
Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
1. Field of the Invention The present invention relates to novel tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidine compounds that are antagonists of alpha V (.alpha.v) integrins, for example .alpha..sub.v.beta..sub.3 and .alpha..sub.v.beta..sub.5 integrins, their
Tricyclic dicarbonyl derivatives
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
This is a 371 application of PCT/EP95/01856, filed May 16, 1995. The present invention is concerned with tricyclic dicarbonyl derivatives of the general formulae ##STR2## wherein R.sup.1 and R.sup.2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino,
Най-пълната база данни за лечебни билки, подкрепена от науката
- Работи на 55 езика
- Билкови лекове, подкрепени от науката
- Разпознаване на билки по изображение
- Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
- Прочетете научни публикации, свързани с вашето търсене
- Търсете лечебни билки по техните ефекти
- Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите
Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания
